LY3405105 is the first orally bioavailable and selective covalent CDK7 inhibitor to reach clinical development. In this phase I, dose-escalation study, the optimal dose and regimen of LY3405105 as a single agent in advanced solid tumors were evaluated, as well as safety, tolerability, pharmacokinetics, and CDK7-target occupancy.
All Keywords
【저자키워드】 Phase I, solid tumors, cyclin-dependent kinase 7, cyclin-dependent kinase inhibitor,
【저자키워드】 Phase I, solid tumors, cyclin-dependent kinase 7, cyclin-dependent kinase inhibitor,